FTC Patent License Rule Sure To Annoy Drugmakers
The Federal Trade Commission's newly finalized rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under the Hart-Scott-Rodino Act will increase costs and delays for the industry...To view the full article, register now.
Already a subscriber? Click here to view full article